JP7084878B2 - 抗第ＩＸ因子Ｐａｄｕａ抗体 - Google Patents

抗第ＩＸ因子Ｐａｄｕａ抗体 Download PDF

Info

Publication number
JP7084878B2
JP7084878B2 JP2018560082A JP2018560082A JP7084878B2 JP 7084878 B2 JP7084878 B2 JP 7084878B2 JP 2018560082 A JP2018560082 A JP 2018560082A JP 2018560082 A JP2018560082 A JP 2018560082A JP 7084878 B2 JP7084878 B2 JP 7084878B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
factor
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018560082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527033A5 (enExample
JP2019527033A (ja
Inventor
ディルク フェルケル，
ロベルト パフリンガー，
ハンスペーター ロッテンシュタイナー，
アルフレート ヴェーバー，
アンドレア エンゲルマイアー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7084878(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2019527033A publication Critical patent/JP2019527033A/ja
Publication of JP2019527033A5 publication Critical patent/JP2019527033A5/ja
Priority to JP2022090787A priority Critical patent/JP2022133276A/ja
Application granted granted Critical
Publication of JP7084878B2 publication Critical patent/JP7084878B2/ja
Priority to JP2024022760A priority patent/JP7671887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/9645—Factor IX (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2018560082A 2016-05-16 2017-05-16 抗第ＩＸ因子Ｐａｄｕａ抗体 Active JP7084878B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022090787A JP2022133276A (ja) 2016-05-16 2022-06-03 抗第ＩＸ因子Ｐａｄｕａ抗体
JP2024022760A JP7671887B2 (ja) 2016-05-16 2024-02-19 抗第ＩＸ因子Ｐａｄｕａ抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662337118P 2016-05-16 2016-05-16
US62/337,118 2016-05-16
US201662340834P 2016-05-24 2016-05-24
US62/340,834 2016-05-24
PCT/US2017/032808 WO2017200981A1 (en) 2016-05-16 2017-05-16 Anti-factor ix padua antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022090787A Division JP2022133276A (ja) 2016-05-16 2022-06-03 抗第ＩＸ因子Ｐａｄｕａ抗体

Publications (3)

Publication Number Publication Date
JP2019527033A JP2019527033A (ja) 2019-09-26
JP2019527033A5 JP2019527033A5 (enExample) 2020-06-18
JP7084878B2 true JP7084878B2 (ja) 2022-06-15

Family

ID=59067875

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018560082A Active JP7084878B2 (ja) 2016-05-16 2017-05-16 抗第ＩＸ因子Ｐａｄｕａ抗体
JP2022090787A Withdrawn JP2022133276A (ja) 2016-05-16 2022-06-03 抗第ＩＸ因子Ｐａｄｕａ抗体
JP2024022760A Active JP7671887B2 (ja) 2016-05-16 2024-02-19 抗第ＩＸ因子Ｐａｄｕａ抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022090787A Withdrawn JP2022133276A (ja) 2016-05-16 2022-06-03 抗第ＩＸ因子Ｐａｄｕａ抗体
JP2024022760A Active JP7671887B2 (ja) 2016-05-16 2024-02-19 抗第ＩＸ因子Ｐａｄｕａ抗体

Country Status (12)

Country Link
US (2) US11098132B2 (enExample)
EP (1) EP3458477B1 (enExample)
JP (3) JP7084878B2 (enExample)
KR (2) KR102625416B1 (enExample)
CN (1) CN109563154B (enExample)
AU (1) AU2017268198C1 (enExample)
BR (1) BR112018073660A2 (enExample)
CA (1) CA3024485A1 (enExample)
IL (1) IL262813B2 (enExample)
RU (2) RU2022108606A (enExample)
SG (1) SG11201809642TA (enExample)
WO (1) WO2017200981A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN110343181B (zh) * 2018-04-08 2022-04-08 苏州康宁杰瑞生物科技有限公司 针对凝血因子ix(fix)的单域抗体
LT3723858T (lt) 2018-12-21 2022-02-10 Kymab Limited Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę
GB202009928D0 (en) * 2020-06-29 2020-08-12 Freeline Therapeutics Ltd Method
KR102749341B1 (ko) * 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
CN116217674B (zh) * 2023-02-07 2024-08-02 湖南九典制药股份有限公司 一种抗菌/抗炎多肽及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064277A1 (en) 2012-10-26 2014-05-01 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US20040096983A1 (en) * 2002-11-14 2004-05-20 Jacobs Merrit N. Wash process for a sample being analyzed
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1876236B9 (en) * 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
US8234784B2 (en) 2008-02-13 2012-08-07 Younger Steven W Valve piston repositioning apparatus and method
WO2014052490A1 (en) * 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2016004113A1 (en) * 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064277A1 (en) 2012-10-26 2014-05-01 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRUDELE, J.M., et al.，"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice."，BLOOD，2015年03月05日，Vol.125, No.10，pp.1553-1561，doi: 10.1182/blood-2014-07-588194
KOENDERMAN, J., et al.，"Factor IX-R338L (Factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism."，THROMBOSIS RESEARCH，2011年，Vol.128, No.6，p.603，doi: 10.1016/j.thromres.2011.07.009
NAIR, N., et al.，"Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy."，BLOOD，2014年05月15日，Vol.123, No,20，pp.3195-3199，doi: 10.1182/blood-2013-10-534032

Also Published As

Publication number Publication date
EP3458477B1 (en) 2025-07-09
CA3024485A1 (en) 2017-11-23
KR102625416B1 (ko) 2024-01-15
NZ747752A (en) 2025-05-30
AU2017268198B2 (en) 2020-09-03
WO2017200981A8 (en) 2018-02-01
RU2018138782A3 (enExample) 2020-07-14
US11999798B2 (en) 2024-06-04
CN109563154A (zh) 2019-04-02
SG11201809642TA (en) 2018-11-29
EP3458477A1 (en) 2019-03-27
JP7671887B2 (ja) 2025-05-02
KR102481704B1 (ko) 2022-12-27
AU2017268198C1 (en) 2020-11-26
IL262813B1 (en) 2025-08-01
US11098132B2 (en) 2021-08-24
WO2017200981A1 (en) 2017-11-23
KR20230006026A (ko) 2023-01-10
JP2024056941A (ja) 2024-04-23
RU2022108606A (ru) 2022-04-11
IL262813B2 (en) 2025-12-01
KR20190006548A (ko) 2019-01-18
RU2018138782A (ru) 2020-06-17
RU2770006C2 (ru) 2022-04-14
JP2022133276A (ja) 2022-09-13
AU2017268198A1 (en) 2018-11-22
CN109563154B (zh) 2024-12-13
US20220056150A1 (en) 2022-02-24
US20190194351A1 (en) 2019-06-27
BR112018073660A2 (pt) 2019-02-19
JP2019527033A (ja) 2019-09-26
IL262813A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
JP7671887B2 (ja) 抗第ＩＸ因子Ｐａｄｕａ抗体
JP5753079B2 (ja) Ｈｅｒ２受容体またはその末端切断変異体を発現する癌を診断するための方法
CN103827144B (zh) 新的抗cxcr4抗体及其用于检测和诊断癌症的用途
TW200823293A (en) Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease
CA3079112A1 (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
CN107849139B (zh) 与人crth2特异性结合的抗体
JP2018086005A (ja) Ｔｅｍ−１診断用抗体
CN112703204B (zh) 针对可溶性bcma的抗体
JP5147696B2 (ja) 可溶型ｌｏｘ−１に対するモノクローナル抗体
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
JP2024530325A (ja) 抗４－１ｂｂナノボディ
JP2024509683A (ja) 抗ｐｔ２１７ ｔａｕ抗体
US20250231195A1 (en) Use of fsh-receptor ligands for diagnosis and therapy of atherosclerosis
RU2773819C2 (ru) Белок, связанный с гликопротеином человека, композиция, фармацевтическая композиция, вектор экспрессии
JP2024508222A (ja) 抗Ｍｃｌ１抗体を投与することによる癌を監視するための材料及び方法
TW201139459A (en) Osteopontin-specific monoclonal antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210531

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220603

R150 Certificate of patent or registration of utility model

Ref document number: 7084878

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250